Cargando…

Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab

Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells. Although advances in treatment have markedly improved survival outcomes for patients with MM, this disease is still considered incurable owing to its high incidence of relapse and refractorin...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Fei, Shen, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340383/
https://www.ncbi.nlm.nih.gov/pubmed/35903924
http://dx.doi.org/10.1177/15330338221106563
_version_ 1784760391438434304
author Shen, Fei
Shen, Weidong
author_facet Shen, Fei
Shen, Weidong
author_sort Shen, Fei
collection PubMed
description Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells. Although advances in treatment have markedly improved survival outcomes for patients with MM, this disease is still considered incurable owing to its high incidence of relapse and refractoriness. Isatuximab is an anti-CD38 monoclonal antibody that can induce apoptosis in myeloma cells through a variety of mechanisms. Many clinical studies have demonstrated the efficacy and efficiency of isatuximab in both relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma, leading to its approval for the treatment of adults with RRMM in combination therapies. In this review, the structure, mechanisms of action, pharmacokinetics, pharmacogenetics, and safety profile of isatuximab in MM are summarized. Additionally, isatuximab is compared with daratumumab in terms of mechanism and efficacy.
format Online
Article
Text
id pubmed-9340383
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-93403832022-08-02 Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab Shen, Fei Shen, Weidong Technol Cancer Res Treat Novel Biomarkers, Molecular Diagnostics and Targeted Therapies of Cancer Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells. Although advances in treatment have markedly improved survival outcomes for patients with MM, this disease is still considered incurable owing to its high incidence of relapse and refractoriness. Isatuximab is an anti-CD38 monoclonal antibody that can induce apoptosis in myeloma cells through a variety of mechanisms. Many clinical studies have demonstrated the efficacy and efficiency of isatuximab in both relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma, leading to its approval for the treatment of adults with RRMM in combination therapies. In this review, the structure, mechanisms of action, pharmacokinetics, pharmacogenetics, and safety profile of isatuximab in MM are summarized. Additionally, isatuximab is compared with daratumumab in terms of mechanism and efficacy. SAGE Publications 2022-07-29 /pmc/articles/PMC9340383/ /pubmed/35903924 http://dx.doi.org/10.1177/15330338221106563 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Novel Biomarkers, Molecular Diagnostics and Targeted Therapies of Cancer
Shen, Fei
Shen, Weidong
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
title Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
title_full Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
title_fullStr Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
title_full_unstemmed Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
title_short Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
title_sort isatuximab in the treatment of multiple myeloma: a review and comparison with daratumumab
topic Novel Biomarkers, Molecular Diagnostics and Targeted Therapies of Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340383/
https://www.ncbi.nlm.nih.gov/pubmed/35903924
http://dx.doi.org/10.1177/15330338221106563
work_keys_str_mv AT shenfei isatuximabinthetreatmentofmultiplemyelomaareviewandcomparisonwithdaratumumab
AT shenweidong isatuximabinthetreatmentofmultiplemyelomaareviewandcomparisonwithdaratumumab